Yajing Chen Sells 2,154 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CFO Yajing Chen sold 2,154 shares of Zai Lab stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total transaction of $38,556.60. Following the transaction, the chief financial officer now directly owns 13,714 shares in the company, valued at $245,480.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Yajing Chen also recently made the following trade(s):

• On Thursday, April 4th, Yajing Chen sold 845 shares of Zai Lab stock. The shares were sold at an average price of $15.67, for a total transaction of $13,241.15.
• On Tuesday, April 2nd, Yajing Chen sold 519 shares of Zai Lab stock. The stock was sold at an average price of $16.15, for a total transaction of $8,381.85.

Zai Lab Trading Down 1.1 %

NASDAQ:ZLAB opened at $17.33 on Friday. Zai Lab Limited has a 52 week low of $13.48 and a 52 week high of $32.60. The company has a fifty day moving average of $18.36 and a 200 day moving average of $20.19.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.38. The firm had revenue of $87.15 million during the quarter, compared to the consensus estimate of $77.07 million. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. During the same period in the prior year, the firm posted ($0.51) earnings per share. On average, sell-side analysts predict that Zai Lab Limited will post -2.78 EPS for the current year.

Institutional Investors Weigh In On Zai Lab

A number of large investors have recently made changes to their positions in ZLAB. Capital World Investors raised its holdings in shares of Zai Lab by 8.9% during the first quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock valued at $91,061,000 after acquiring an additional 465,337 shares in the last quarter. Wellington Management Group LLP raised its holdings in Zai Lab by 177.6% in the 4th quarter. Wellington Management Group LLP now owns 5,336,457 shares of the company’s stock worth $145,845,000 after purchasing an additional 3,413,829 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Zai Lab by 9.6% in the 1st quarter. Janus Henderson Group PLC now owns 4,428,011 shares of the company’s stock worth $70,924,000 after purchasing an additional 387,729 shares during the period. Bamco Inc. NY boosted its stake in shares of Zai Lab by 7.3% during the 1st quarter. Bamco Inc. NY now owns 1,599,865 shares of the company’s stock valued at $25,630,000 after purchasing an additional 108,991 shares in the last quarter. Finally, Rock Springs Capital Management LP increased its position in shares of Zai Lab by 1.2% during the third quarter. Rock Springs Capital Management LP now owns 1,237,023 shares of the company’s stock valued at $30,072,000 after buying an additional 14,600 shares during the period. 41.65% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research note on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $64.57.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.